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ABSTRACT
RNA-seq experiments previously performed by our
laboratories showed enrichment in intronic se-
quences and alterations in alternative splicing in
dengue-infected human cells. The transcript of the
SAT1 gene, of well-known antiviral action, displayed
higher inclusion of exon 4 in infected cells, leading
to an mRNA isoform that is degraded by non-sense
mediated decay. SAT1 is a spermidine/spermine
acetyl-transferase enzyme that decreases the reser-
voir of cellular polyamines, limiting viral replica-
tion. Delving into the molecular mechanism under-
lying SAT1 pre-mRNA splicing changes upon vi-
ral infection, we observed lower protein levels of
RBM10, a splicing factor responsible for SAT1 exon
4 skipping. We found that the dengue polymerase
NS5 interacts with RBM10 and its sole expression
triggers RBM10 proteasome-mediated degradation.
RBM10 over-expression in infected cells prevents
SAT1 splicing changes and limits viral replication,
while its knock-down enhances the splicing switch
and also benefits viral replication, revealing an anti-
viral role for RBM10. Consistently, RBM10 deple-
tion attenuates expression of interferon and pro-
inflammatory cytokines. In particular, we found that
RBM10 interacts with viral RNA and RIG-I, and even
promotes the ubiquitination of the latter, a crucial
step for its activation. We propose RBM10 fulfills di-
verse pro-inflammatory, anti-viral tasks, besides its
well-documented role in splicing regulation of apop-
totic genes.
INTRODUCTION
Dengue virus (DENV) is the most prevalent arbovirus
worldwide, found in over 100 tropical and sub-tropical
countries (1). It is transmitted mainly by Aedes aegypti and
Aedes albopictus mosquitoes. Over half of the global pop-
ulation is at risk for dengue infection, with 100 million
symptomatic cases being reported every year (2). DENV
is part of the Flaviviridae family, which also includes Zika
(ZIKV), yellow fever, Japanese encephalitis, and West Nile
viruses. They are enveloped, icosahedral viruses, with a
positive-sense and single-stranded RNA (ssRNA) genome
that encodes one open reading frame that, upon proteolytic
processing, gives rise to three structural (capsid, precursor
membrane (prM), and envelope) and seven nonstructural
(NS) proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b, and
NS5). The genome is approximately 11 kb in length, con-
taining a type I cap at the 5′ end and lacking a 3′ poly(A) tail
(3,4). Like other RNA viruses, the DENV genome encodes
a limited set of proteins, relying on the host machinery for
productive replication (5).
For DENV, as for many RNA viruses, an initial step in
the establishment of the cellular innate antiviral response
is the sensing of cytosolic RNA by retinoic acid-inducible
gene I (RIG-I) like receptors (RLRs). Expressed by most
cells of the human organism, RLRs belong to the family of
DExD/H-box helicases and include three members of rel-
evance: RIG-I, melanoma differentiation-associated anti-
gen 5 (MDA5), and laboratory of genetics and physiology
2 (LGP2) (6). Studies of gene-deficient mice indicate that
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RLRs are critical sensors of viral infection. RLRs are ex-
pressed at low concentrations in the resting cell and, upon
stimulation by viral infection, they trigger signaling path-
ways that promote the IRF3-, IRF7-dependent expression
of type I and type III interferons (IFNs), as well as the
NF-kappa B-dependent expression of pro-inflammatory
cytokines. In the case of DENV, it was reported that RIG-I
recognizes the 5′ region of the viral genome, in particular
a double stranded RNA structure bearing 5′-triphosphates
that is only present during viral genome replication (7).
This recognition is followed by a multi-step activation pro-
cess including conformational changes and several post-
translational modifications of RIG-I that are crucial to un-
leash its full activity and consequently its downstream sig-
naling pathway. One of the first RIG-I post-translational
modifications is the non-degradative ubiquitination at mul-
tiple sites, involving the activity of different ubiquitin E3
ligases (8,9).
Several transcriptomic studies identified
spermidine/spermine-N1-acetyltransferase (SAT1) as
a downstream target of type I IFN stimulation in cell cul-
ture and in vivo (10). SAT1 regulates the cellular content of
polyamines, which are small, abundant, aliphatic molecules
present in all mammalian cells. Within the context of the
cell, they play a myriad of roles, from modulating nucleic
acid conformation to promoting cellular proliferation and
signaling (11). In addition, polyamines have emerged as im-
portant molecules in virus-host interactions. Many viruses
have been shown to require polyamines for one or more
aspects of their replication cycle, including DNA and RNA
polymerization, nucleic acid packaging, and protein syn-
thesis (12,13). When SAT1 acetylates polyamines, they are
either secreted from the cell or oxidized by acetylpolyamine
oxidase. The fact that SAT1 reduces polyamine availability
and is upregulated by IFN assigns it an anti-viral role (14).
Alternative splicing provides an important regulatory
step for the control of SAT1 mRNA production. SAT1
pre-mRNA can undergo alternative splicing giving rise to
‘SAT1-IN’ mRNA isoform, which includes an additional
110-nt exon containing multiple premature termination
codons downstream of constitutive exon 3 and upstream
of constitutive exons 5, 6 and 7. This renders the SAT1-IN
splice variant a target for nonsense-mediated mRNA decay
(NMD) (Figure 1A). Polyamines or analogs inhibit inclu-
sion of this ‘poison’ exon, leading to a higher proportion of
stable and protein-coding SAT1 mRNA, the isoform that
lacks exon 4 ‘SAT1-EX’ (15,16). The rapid loss of SAT1-
IN mRNA via NMD may limit any accumulation in cells,
although SAT1-IN mRNA has been found to accumulate
in response to X-rays (17), viruses (18) and hypoxia (19).
In our previous work, in which we proposed that DENV
NS5 protein hijacks the cellular spliceosome and modulates
splicing, RNA-seq experiments revealed an accumulation
of SAT1-IN mRNA upon DENV infection (20).
SAT1 pre-mRNA alternative splicing is known to be reg-
ulated by the RNA-binding protein RBM10 (21). This pro-
tein contains two RNA recognition motifs (RRM), two zinc
fingers and one G patch motif, features that are shared
with other splicing-related factors, including protein com-
ponents of the small nuclear ribonucleoprotein particles
(snRNPs) that constitute the spliceosome (22,23). Pro-
teomic studies carried out by several laboratories detected
the association of RBM10 with purified splicing complexes
(24–29), further supporting its role as a regulator of pre-
mRNA splicing. Moreover, RBM10 and its paralog RBM5
have been shown to regulate alternative splicing of apopto-
sis related genes, assigning both factors a tumor suppres-
sor role (30–33). RNA-seq experiments identified signifi-
cant splicing changes following RBM10 depletion or over-
expression in HEK 293T cells. A deeper analysis of the af-
fected alternative splicing events identified a predominance
of enhanced exon skipping, correlating with a robust bind-
ing of RBM10 to upstream and downstream introns flank-
ing the corresponding alternative exons (34). In addition,
RBM10 has been reported to regulate its own alternative
splicing (35), by promoting exon 6 and 12 skipping. This
gives rise to NMD-targeted mRNA isoforms regulating
its own protein levels. Importantly, lung adenocarcinoma-
associated mutations affecting splice sites of RBM10 exons
6 or 12 abolish exon inclusion and correlate with reduced
RBM10 mRNA levels. Of note, recent mass spectrometry-
based interactome studies revealed that RBM10 interacts
with ZIKV NS5 protein, the viral polymerase that was also
reported to bind several core splicing components, both in
Zika and DENV viruses (20,36).
Previous work from our laboratories has revealed that
DENV infection as well as DENV NS5 per se trigger
changes in alternative splicing patterns of human host cell
lines (20). Here, we report that among several affected
pre-mRNAs, SAT1 splicing patterns are modulated upon
DENV infection. Consistent with this, we observed a de-
crease in RBM10 protein levels, a splicing factor known
to regulate SAT1 splicing (21). We found that DENV NS5
binds RBM10 and mediates its proteasomal degradation.
Additionally, RBM10 over-expression not only restores
SAT1 splicing to the levels observed in mock conditions
but also attenuates DENV replication, while RBM10 de-
pletion enhances viral proliferation. These observations led
us to assign an anti-viral role to RBM10, supported also by
the evidence that transcriptional induction downstream of
RLR activation is attenuated when cells are infected with
DENV in the context of RBM10 knock-down. We propose
that RBM10 exerts this pro-inflammatory function, at least
in part, by interacting with RIG-I receptor, which could be
facilitated by cytoplasmic DENV RNA, independently of
the type I IFN receptor (IFNR) signaling pathway. In line
with this idea, we show that RBM10 over-expression en-
hances RIG-I ubiquitination, a crucial step along the acti-
vation of this viral sensor required for the establishment of
a robust innate immune response. In this context, it is possi-
ble that DENV protein NS5 restricts RBM10 from playing
an anti-viral role, not only by physically interacting with it,
but also by triggering its proteasomal degradation.
MATERIALS AND METHODS
Cell lines
A549 cells (human lung adenocarcinoma epithelial cell line,
ATCC, CCL-185) were maintained in Dulbecco’s modified
Eagle’s medium/F-12 (Ham’s) and HEK 293T cells (human
embryonic kidney cell lines, ATCC CRL-1573) were main-
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media was supplemented with 5% fetal bovine serum and 50
g/ml gentamicin while the HEK 293T media with 10% fe-
tal bovine serum, 100 U/ml penicillin and 100 g/ml strep-
tomycin.
DENV infections, IFN treatment and DNA/RNA transfec-
tions
DENV-2 infections, strain 16681, were performed with a
multiplicity of infection (MOI) ∼1. The viral adsorption
was carried out at 4◦C with agitation and, after one hour
of incubation, replaced with fresh media. For IFN treat-
ments, 50 000 U/ml of interferon  2b (Biosidus) were
added to cell media. Plasmid DNA and siRNAs (Dharma-
con) were transfected with 293-Free™ Transfection Reagent
(Merck) and Lipofectamine 2000 (Thermo Fisher), respec-
tively, according to manufacturer’s instructions. Poly I:C
intracellular administration was performed by transfecting
polyinosinic-polycytidilic acid [poly(I:C)] HMW (Invivo-
Gen) with Lipofectamine 2000, at a ratio of 10:1 and a final
concentration of Poly I:C of 10 g/ml. Treatment with JAK
inhibitor I (SC-204021) was performed at a final concentra-
tion of 1 M for 24 h and the corresponding control was
performed with the appropriate volume of DMSO.
T7-RBM10 plasmid was kindly provided by Dr Cáceres’
laboratory (MRC Institute of Genetics and Molecular
Medicine, University of Edinburgh, UK) (37), Streptag-
NS5 has been previously described (20), and Flag-RIG I
plasmid was kindly provided by Dr Fujita’s laboratory (In-
stitute for Frontier Life and Medical Sciences, Kyoto Uni-
versity, Japan).
End point and quantitative PCR
Total cellular RNA was isolated by using Trizol (In-
vitrogen) and reverse transcribed with random deca-
oligonucleotide primer mix. End-point PCR products were
electrophoresed in 1–1.5% ethidium bromide-containing
agarose gels. Quantitative PCRs (qPCRs) were performed
by using SYBR Green dye and specific primers for different
pre-mRNAs, mRNAs and DENV RNA genome. GAPDH
mRNA was used as a control housekeeping gene. The spe-
cific primers used for PCR and qPCR are listed in Supple-
mentary Table S1.
When indicated, RNA samples were prepared from dif-
ferent subcellular fractions: chromatin; nucleoplasm or cy-
toplasm obtained as described in Supplementary Material.
DENV replication, Poly I:C intracellular administration and
IFN treatment in the context of RNA interference
RNA interference experiments were carried out using
siGENOME ON-TARGET plus SMART pool siRNA
oligonucleotides (Dharmacon RNA Technologies). The
control non-related siRNA used was directed against fire-
fly luciferase. Twenty-four hours after seeding in 24-well
plates, A549 cells were transfected with the corresponding
siRNA. Briefly, 20 pmol of siRNA in 50 l of Opti-MEM
(Invitrogen) were mixed with 2 l of Lipofectamine in 50
l of Opti-MEM and incubated for 20 min. The mix was
added to a 50% confluent A549 cells monolayer and incu-
bated overnight. After 24 h of transfection, cells were mock
infected or infected, as indicated above. Alternatively, cells
were transfected with Poly I:C or treated with IFN. RNA
was purified using Trizol at 48 h post-infection (hpi), at 9 h
after Poly I:C transfection or 24 h after IFN addition. RT-
PCR and qPCR were performed as previously described us-
ing primers listed on Supplementary Table S1.
Antibodies
Rabbit polyclonal antibodies against RBM10 were
purchased from Abcam (ab72423) and Sigma-Aldrich
(HPA034972), anti-RIG-I from Santa Cruz (D-12,
SCBT), anti-tubulin (mouse monoclonal) from Sigma-
Aldrich (T9026), anti-T7 tag (mouse monoclonal) from
Merck (69522), anti-H3 (rabbit polyclonal) from Abcam
(ab1791), and anti-dsRNA antibody from SCICONS
(mAb J2). Anti-NS5 antibodies (rabbit polyclonal and
mouse polyclonal) were obtained in our laboratory and
anti-Streptag antibody (mouse monoclonal) was purchased
from EMD Millipore (71590-3).
Western blots
Protein samples were resolved by SDS-PAGE and trans-
ferred to nitrocellulose membranes (GE Healthcare Amer-
sham). Membranes were blocked and then incubated with
primary antibodies. After washing, membranes were in-
cubated with IRDye® 800CW or 680RD (LI-COR Bio-
sciences) secondary antibodies. Bound antibody was de-
tected using an Odyssey imaging system (LI-COR Bio-
sciences). Western blots were performed at least three times
from independent experiments and representative images
are shown in each case.
Immunofluorescence assays
Immunofluorescence assays were performed as previously
described (38). Briefly, A549 cells were seeded into 24-well
plates containing glass coverslips. Twenty-four hours later,
cells were mock infected or infected with DENV. After 24
h, coverslips were collected and the cells were fixed with
paraformaldehyde 4% in PBS pH 7.4 at room temperature
for 10 min. PFA-fixed cells were then permeabilized with
1% Triton X-100 for 5 min at room temperature. Coverslips
were blocked with BSA 3% in PBS and incubated with pri-
mary antibody (appropriate dilution in blocking solution)
for 1 hour at RT. After three washes with PBS, incubation
with secondary antibody (Alexa Fluor® 488 and 647, 1:500
in blocking solution) was performed for 1 h and washed 4
times with PBS. Coverslips were mounted with a drop of
mounting medium (Vectashield) and images were obtained
with an Olympus FV300 confocal microscope. Fluorescence
intensity analysis of images was performed with Cell Pro-
filer software (v 3.1.5) after generating a suitable pipeline
for this purpose.
Subcellular fractionation
Preparation of nuclear and cytoplasmic proteins from A549
cells was conducted following a small-scale fractionation
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mock infected or infected with DENV. After 48 h, cells were
harvested using a cell scraper and washed with 0.5 ml of
PBS. A 0.1 ml aliquot was separated as whole cell extract
and the rest pelleted at 100 rcf for 2 min. After centrifuga-
tion, cell pellets were resuspended in HLB buffer (10 mM
Tris–HCl pH 7.5, 10 mM NaCl, 3 mM MgCl2, 0.3% Igepal
CA630, 10% glycerol and 1× protease inhibitors, Roche).
Incubation was carried out on ice for 10 min. Samples were
centrifuged at 4◦C and 800 g for 8 min. The pellet corre-
sponds to intact nuclei and the supernatant to cytoplasmic
fraction. 2× Laemmli sample buffer was added to all frac-
tions and they were sonicated twice for 5 s each, heated for
5 min at 95◦C and analyzed by SDS PAGE/western blot.
Immunoprecipitation of RNP complexes
Cells were harvested and lysed in RIPA buffer (50 mM
Tris–HCl (pH 7.5), 1% (v/v) NP-40, 0.5% (w/v) sodium
deoxycholate, 0.05% (w/v) SDS, 1 mM EDTA, 150 mM
NaCl) containing complete protease inhibitor and RNasin
(Promega). Extracts were sonicated at high amplitude with
three 10-s bursts, and insoluble material was pelleted. Anti-
RBM10 or control IgG were added to the supernatant
and incubated overnight. When indicated, RNAse A (0,1
mg/ml) was previously added to lysates. Complexes were
incubated with GammaBind G sepharose beads (Thermo
Fisher) for 1 h and washed three times in wash buffer (50
mM Tris–HCl (pH 7.5), 0.1% (v/v) NP-40, 1 mM EDTA,
125 mM NaCl). For western blot analysis, beads were resus-
pended in 2× Laemmli sample buffer. For RNA immuno-
precipitation analysis, beads were resuspended in Trizol
and subjected to RNA extraction followed by RT-qPCR.
cDNA was prepared from one-half of the RNA using 10-
mer random primers. The cDNA and no-reverse transcrip-
tion control were analyzed by qPCR with primer pairs span-
ning DENV RNA and SAT1 pre-mRNA as detailed in the
primer list (Supplementary Table S1) and visualized as the
average ratio of immunoprecipitated RNA divided by the
input.
Purification of 6xHis-ubiquitin-conjugated proteins
HEK 293T cells were transfected in 35-mm culture wells
with the indicated plasmids. After 48 h, His-ubiquitin con-
jugates were purified under denaturing conditions using
Ni-NTA-agarose beads according to the manufacturer’s in-
structions (Qiagen). Briefly, transfected cells were harvested
in ice-cold PBS. An aliquot was taken as input and the
remaining cells were lysed in 6 M guanidinium–HCl con-
taining 100 mM Na2HPO4/NaH2PO4, 10 mM Tris–HCl
pH 8.0, 5 mM imidazole. Samples were sonicated to re-
duce the viscosity and proteins were purified using Ni-
NTA beads (Qiagen) according to (40). Samples were subse-
quently washed with wash buffer I (8 M urea, 10 mM Tris–
HCl pH 8.0, 100 mM Na2HPO4/NaH2PO4, 5 mM imida-
zole), wash buffer II (8 M urea, 10 mM Tris–HCl, 100 mM
Na2HPO4/NaH2PO4, 0.2% Triton X-100, 5 mM imidazole,
pH 6.3), and wash buffer III (8 M urea, 10 mM Tris–HCl
pH 6.3, 100 mM Na2HPO4/NaH2PO4, 0.1% Triton X-100,
5 mM imidazole. Samples were eluted in 2× Laemmli sam-
ple buffer containing 200 mM imidazole for 5 min at 95◦C.
Statistics
Typically, three independent experiments in triplicate re-
peats were conducted for each condition examined. Av-
erage values are shown with standard deviation and P-
values, measured with a paired two-tailed t-test. Significant
P-values are indicated by the asterisks above the graphs
(***P < 0.001; **P < 0.01; *P < 0.05).
RESULTS
Dengue virus infection modulates SAT1 alternative splicing
As mentioned earlier, SAT1 has received increasing atten-
tion for its anti-viral role through depletion of the cellular
polyamines required for viral replication. It caught our at-
tention that RNA-seq experiments previously performed by
our laboratories (20) evidenced changes in the splicing pat-
tern of SAT1, among several other splicing events that were
altered upon DENV infection (Figure 1A and B). In partic-
ular, we observed an increase in reads corresponding to al-
ternative exon 4 at 24 and 36 hours post-infection (hpi) com-
pared to uninfected (Mock) cells. SAT1 mRNA isoforms ei-
ther containing or lacking exon 4 were detected by RT-PCR
(Figure 1A and C). We proceeded to quantify them by real
time PCR (qPCR) and, confirming our previous RNA-seq
results, a significant increase in exon 4 inclusion at 24 hpi
was clearly observed. This effect was also observed after in-
fecting A549 cells with ZIKV, another member of the Fla-
viviridae family (Figure 1A and D).
SAT1 splicing changes were analyzed by RT-qPCR
throughout a wider time frame (0–36 hpi). To monitor in-
fection over time, we quantified viral genome within cells
and induction of Interferon Stimulated Gene 15 (ISG15) by
RT-qPCR (Figure 1E and F), which is slightly delayed from
viral replication detection, in agreement with previous re-
ports (41,42). The progress of the infection was also verified
by quantification of virus titers by plaque assay (Figure 1E,
PFU/ml). We actually found that exon inclusion (IN) over
exon exclusion (EX) ratio decreases at 6 hpi due to SAT1-
EX enhancement (Figure 1G and H), which is consistent
with the well-known SAT1 early induction as an anti-viral
protein (10). However, IN/EX ratio is reversed already at
24 hpi and keeps increasing until 36 hpi (Figure 1G). This
reversion in splicing IN/EX ratio is explained by SAT1-IN
isoform accumulation and seems to mitigate the early in-
duction of SAT1-coding isoform (EX) (Figure 1H). Tak-
ing into account that the NMD pathway takes place in the
cytoplasm, the detection of SAT1 splicing changes at the
level of chromatin-associated RNA, as well as nucleoplas-
mic RNA, rules out a possible accumulation of the SAT1-
IN isoform as a mere consequence of NMD attenuation due
to the translation blockade that has been reported to take
place upon viral infection (43) (Supplementary Figure S1).
Altogether these results corroborate a change in the splicing
pattern of SAT1 pre-mRNA, increasing the proportion of
the non-coding isoform, as a result of DENV infection.
RBM10 regulates SAT1 alternative splicing and modulates
DENV infection
As reported in earlier studies, RBM10 role in alternative
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Figure 1. Dengue virus infection modulates SAT1 alternative splicing. (A) Diagram of SAT1 pre-mRNA splicing giving rise to two different splicing
isoforms, a protein coding (EX isoform) and a non-coding one (IN isoform). Arrows indicate the position of the primer pairs used for end-point and
qPCR. (B) SAT1 RNA-seq reads indicating the position of alternative 110 nt-exon 4 from mock and dengue infected A549 cells (20) at 24 h post-infection
(hpi). (C) Reverse transcription followed by end-point PCR identifying SAT1 splicing isoforms by electrophoresis in agarose gel, from total RNA of A549
cells at 24 hpi. (D) Quantified SAT1 inclusion/exclusion ratio with specific primers for each splicing isoform by RT-qPCR, from total RNA of A549 cells at
24 hpi with DENV or ZIKV. (E–H) RT-qPCRs of viral RNA (E), Interferon Stimulated Gene 15 (ISG15) (F), SAT1-IN and EX isoforms (G) and SAT1-IN
and EX isoforms relative to SAT1 pre-mRNA (H) from A549 cells at the indicated time points post-infection. Viral infection was also monitored by plaque
formation assay (PFU: Plaque Forming Units) (E). Average values from triplicates are shown with standard deviation and p-values, determined using a
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exon 4 has been identified as one of its targets (21). We
assessed RBM10 activity either by its depletion or over-
expression in A549 cells. We found a significant increase
of SAT1 exon 4 inclusion when RBM10 was silenced by
siRNA, and, consistently, the opposite effect when T7-
tagged RBM10 was over-expressed in these cells (Figure
2A and B). siRNA specificity as well as RBM10 action
on SAT1 splicing were validated by rescue experiments in
which the effect of RBM10 depletion on SAT1 alternative
splicing was reversed by over-expression of T7-RBM10 us-
ing an expression vector that lacks full complementarity
with the pool of RBM10 siRNAs (Supplementary Figure
S2A and B).
To further explore this result, we used the RBM10
depletion/over-expression background to evaluate SAT1
alternative splicing upon DENV infection. We transfected
cells with siRBM10 or T7-RBM10 expression vector and
24 h later, infected them with DENV. Remarkably, RBM10
depletion enhanced the effect of viral infection on IN/EX
ratio even further, whereas T7-RBM10 over-expression
was able to prevent the infection-triggered increase of the
IN/EX ratio at 48 hpi, as assayed by RT-PCR (Supple-
mentary Figure S2C) and qPCR (Figure 2C). Moreover, we
quantified viral genome within cells by qPCR and found
higher levels of viral replication in RBM10-depleted cells,
compared to siControl-transfected cells (Figure 2E, left
panel). In contrast, viral replication was severely attenuated
when RBM10 was over-expressed, compared to transfec-
tion with an empty vector (Figure 2E, right panel). The lat-
ter result was further confirmed by plaque assay (PFU/ml),
a less sensitive but widely used measurement for viral ti-
tering. In all conditions, RBM10 protein levels were mon-
itored by western blot (Figure 2D). These results lead us
to propose an anti-viral role for RBM10, which is consis-
tent with its already characterized pro-apoptotic function.
Overall, advanced DENV infection seems to have the same
effect on SAT1 pre-mRNA splicing as RBM10 knock-down
(Figure 2F), which actually promotes viral replication and
has an additive effect on SAT1 splicing when combined
with infection (Figure 2C left panel and Supplementary
Figure S2C).
To examine the global impact of DENV infection on
RBM10 regulated splicing, we analyzed our RNA-seq data
(20) together with the data set already published by Wang
et al. (34), which evaluated differentially spliced exons upon
RBM10 knock-down or over-expression in HEK 293T. The
fact that we found several differentially spliced alternative
exons that are shared by both data sets (Supplementary Ta-
ble S2) suggests that RBM10 might account for DENV-
triggered host cell splicing modulation beyond the partic-
ular case of SAT1 transcript. In this context, it is tempting
to speculate that RBM10 action on a given combination of
pre-mRNA targets could provide a more restrictive cellular
milieu for viral replication, while viral tampering with the
splicing pattern of several RBM10-dependent events upon
infection could revert this situation, thus promoting a more
permissive cellular environment for viral proliferation. It is
likely that higher sequencing depth from RBM10-depleted
infected cells would shed more light on this changing alter-
native splicing scenario.
DENV NS5 targets RBM10 for proteasomal degradation
Since RBM10 knock-down seemed to promote viral repli-
cation and RBM10 also accounted for many splicing
changes observed upon DENV infection, we wondered
whether DENV had any impact on RBM10. Therefore, pro-
tein levels were analyzed by western blot assay showing a
decrease upon DENV infection (Figure 3A). This observa-
tion does not seem to be cell-type dependent, since it was
observed both in A549 and HEK 293T cells (Supplemen-
tary Figure S3A). Additionally, and as previously reported,
A549 cells have less RBM10 mRNA than HEK 293T cells,
which inversely correlates with dengue viral replication abil-
ity within these two cell lines (Supplementary Figure S3B
and C).
Subcellular fractionation evidenced that RBM10 co-
fractionates with the DENV NS5 protein, which was
also observed by indirect immunofluorescence, being both
mainly detected within cell nucleus (44,45) (Figure 3B and
C). RBM10 has already been reported to interact with
ZIKV NS5 (36) and, in agreement with all these findings,
RBM10 co-immunoprecipitated with DENV NS5, even af-
ter treatment with RNase A, suggesting that this interaction
is RNA-independent (Figure 3D). In our previous report,
mass spectrometry experiments failed to identify RBM10
as an NS5 partner (20). Nevertheless, we found that several
spliceosomal proteins, in particular those belonging to U5
snRNP, were pulled down together with NS5. Therefore, we
suggest that RBM10 might interact with NS5, not necessar-
ily as a direct partner but in the context of active spliceo-
somes. However, and in contrast to RBM10, none of the
spliceosomal proteins that were found to co-precipitate with
NS5 in our previous study showed changes in protein levels
upon DENV infection (20). We then wondered what could
be the mechanism responsible for RBM10 decrease, and
whether NS5 alone could be the main effector. To address
this, we transfected increasing amounts of NS5 in A549 cells
and after 48 h assessed RBM10 protein levels by western
blot. It was indeed of note that RBM10 levels decreased
with NS5 over-expression, and that this effect was no longer
observed when proteasome was inhibited by MG132 (Fig-
ure 3E and Supplementary Figure S4A), neither when cells
were treated with IFN nor transfected with Poly I:C, in
the absence of infection or NS5 expression (Supplementary
Figure S4B). These results led us to conclude that DENV
NS5 protein was targeting RBM10 for proteasomal degra-
dation. We then analyzed SAT1 splicing patterns after sole
NS5 over-expression. In agreement with previous findings,
the inclusion over exclusion ratio increased similarly to an
RBM10 knock-down scenario, and concomitantly with a
decrease in RBM10 levels (Figure 3F and Supplementary
Figure S4A). This observation can be explained by NS5-
targeted RBM10 down-regulation but also by the already
mentioned evidence that supports NS5 intrusion into cellu-
lar spliceosomes (20).
RBM10 is involved in the RLR signaling pathway
Considering that DENV triggered a decrease in RBM10
protein levels, a condition that according to the aforemen-
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Figure 2. RBM10 regulates SAT1 alternative splicing and modulates DENV infection (A, B) Quantified inclusion/exclusion ratio in A549 cells either
transfected with siRNA against RBM10 (A) or an expression vector for T7-RBM10 (B). (C) RNA from A549 cells transfected with the indicated siRNAs
or DNA plasmids for 24 h and infected with DENV for additional 48 h was quantified by RT-qPCR for SAT1 inclusion/exclusion ratio. (D) RBM10
knock-down and over-expression in A549 infected cells were monitored by western blot (M: Mock; DV: DENV). (E) Viral infection was monitored by
RT-qPCR of viral RNA and by plaque formation assay (PFU: Plaque Forming Units). Average values from triplicates are shown with standard deviation
and P-values, determined using a paired two-tailed t-test. Significant p-values are indicated by the asterisks above the graphs (***P < 0.001; **P < 0.01;
*P < 0.05). (F) Model of SAT1 pre-mRNA splicing regulation upon RBM10 protein level alterations or DENV infection.
depletion/over-expression background to analyze the cel-
lular innate immune response upon DENV infection (Fig-
ure 4). We quantified IFNα, RIG-I, IL-8 and ISG15 mR-
NAs by RT-qPCR and detected that DENV-triggered in-
duction of these transcripts was abolished when RBM10
was silenced (Figure 4A). In contrast, over-expression of
T7-RBM10 induced all of these transcripts even in the
absence of infection (Figure 4B). In every case, RBM10
protein levels were monitored by western blot (Figure
4C). This led us to propose a possible involvement of
RBM10 in the RLR signaling pathway, which senses vi-
ral cytosolic RNA and transiently induces the expression of
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Figure 3. DENV NS5 interacts with RBM10 and targets it for proteasomal degradation. (A) A549 cells were infected with DENV for 48 h and whole
cell lysates were analyzed by western blot of RBM10, tubulin and NS5. (B) A549 cells were infected with DENV for 48 h and subjected to subcellular
fractionation. Western blot of RBM10, tubulin, histone H3 and NS5 was performed from WCE: whole cell extract; C: cytoplasm and N: nucleus. (C) A549
cells were infected with DENV for 48 h and subjected to indirect immunofluorescence of RBM10 and NS5. (D) Western blot of T7-immunoprepicitated
RBM10 and co-precipitated Streptag-NS5 in the absence or presence of RNase A. (E) A549 cells were transfected with empty vector or Streptag-NS5
expression vector (0.1, 0.5 and 1 g) and treated with 2 M MG132 for 3 h. RBM10, NS5 and tubulin levels were assessed by western blot. (F) A549
cells were transfected with empty vector or NS5 expression vector and after 48 h SAT1 inclusion/exclusion ratio was quantified by RT-qPCR. Average
values from triplicates are shown with standard deviation and p-values, determined using a paired two-tailed t-test. Significant P-values are indicated by
the asterisks above the graphs (***P < 0.001; **P < 0.01; *P < 0.05).
Supporting a role for RBM10 in the innate immune re-
sponse, we found that RBM10 depletion also interferes with
the induction of Type I IFN (IFNβ) and ISGs (ISG15 and
IFIT1) mRNAs upon cellular treatment with Poly I:C, a
synthetic analogue of viral RNA (Figures 4D and 5A).
Remarkably, these results point to a more general and
widespread role of RBM10 in modulating the innate im-
mune response, as part of a defense mechanism that could
be even extrapolated to other RNA viruses.
To further dissect RBM10 action, we took advantage of
the Poly I:C treatment as a way of inducing the innate im-
mune response in the absence of viral infection and there-
fore in the absence of any viral counteracting activity. We
thus combined RBM10 depletion, intracellular administra-
tion of Poly I:C and treatment of A549 cells with a kinase
inhibitor that specifically blocks the activity of the Janus ki-
nase (JAK), a protein required for the activation of IFNR






/nar/advance-article-abstract/doi/10.1093/nar/gkaa340/5841132 by guest on 27 M
ay 2020





Figure 4. RBM10 is involved in the anti-viral innate response. (A–C) A549 cells were transfected with the indicated siRNAs (40 nM) or expression vectors
(200 ng) for 24 h and infected with DENV for additional 48 h. RIG-I, IFN α, IL-8 and ISG15 mRNA levels were analyzed by RT-qPCR (A, B) and
RBM10 and tubulin protein levels by western blot (M: Mock; DV: DENV) (C). (D) A549 cells were transfected with the indicated siRNAs (40 nM) for 72
h during which, the last 9 h included Poly I:C (10 g /ml) intracellular administration. Upon harvesting, RNA was prepared and analyzed by RT-qPCR
for ISG15 and IFIT1 mRNAs. Average values from triplicates are shown with standard deviation and P-values, determined using a paired two-tailed t-test.
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Figure 5. RBM10 is involved in the RLR signaling pathway. (A) A549 cells
were transfected with the indicated siRNAs (40 nM) for 48 h, then mock
treated (DMSO) or treated with 1 M JAK inhibitor for additional 24 h
during which, the last 9 h included Poly I:C intracellular administration.
RNA was prepared and analyzed by RT-qPCR for IFN β. (B and C) A549
cells were transfected with the indicated siRNAs (40 nM) for 24 h and then
treated with IFN  (50 000 U/ml) for additional 24 h. ISG15 (B) and IL-8
(C) mRNA levels were analyzed by RT-qPCR. Average values from trip-
licates are shown with standard deviation and P-values, measured with a
paired two-tailed t-test. Significant P-values are indicated by the asterisks
above the graphs (***P < 0.001; **P < 0.01; *P < 0.05).
that the effect of RBM10 silencing on Poly I:C-triggered
INFβ induction is not significantly altered by inhibition of
the IFNR downstream pathway (Figure 5A). The efficacy
of the JAK inhibitor was monitored by measuring ISG15
mRNA levels, as ISG15 promoter is one of the targets of the
JAK-STAT signaling cascade downstream of IFNR (Sup-
plementary Figure S5A). The above results are in agreement
with the fact that knocking down RBM10 does not impair
neither ISG15 nor IL-8 induction upon IFN treatment (Fig-
ure 5B and C), while it does so upon DENV infection, as al-
ready shown in Figure 4A. In summary, these data point to
a possible action of RBM10 in the RLRs signaling cascade
and independently of the IFNR signaling pathway.
Since RLR signaling begins in the cytoplasm, we also
analyzed any possible changes in the sub-cellular distribu-
tion of RBM10 upon infection. Detection of endogenous
RBM10 as well as viral RNA by immunofluorescence sug-
gests a decrease in the ratio of RBM10 nuclear to cytoplas-
mic localization upon viral infection (Figure 6A). Whether
this partial re-distribution can account for the observed
changes in RBM10-mediated alternative splicing awaits fur-
ther investigation. We then tested the interaction between
RBM10 and RIG-I, the receptor involved in viral RNA
recognition, by co-immunoprecipitation and found that not
only do they interact (Figure 6B), but also that RBM10 co-
precipitates with DENV RNA in A549 infected cells (Fig-
ure 6C, gray bars), suggesting these two proteins could be
part of cytoplasmic ribonucleoprotein complexes. However,
the interaction between RIG-I and RBM10 was also de-
tected upon IFN treatment and even maintained in the pres-
ence of RNase (Figure 6B), which suggests that the viral
RNA is not strictly necessary but might contribute to the
association between these two proteins. Remarkably, in in-
fected cells we also detected a smaller fraction of RBM10-
bound SAT1 pre-mRNA compared to mock conditions
(Figure 6C, black bars). In this context, a large pool of
RBM10-free SAT1 pre-mRNA is processed towards the
exon 4-containing isoform, ultimately favoring viral repli-
cation. These observations could be interpreted as two sides
of the same coin. On one side, RBM10 may exert its antivi-
ral role in part by stimulating the innate immune response,
possibly through its interaction with RIG-I and the viral
RNA and/or through its splicing regulatory function. On
the other side, viral counteracting activities tend to dimin-
ish RBM10 levels and therefore RBM10 action on SAT1
and/or other pre-mRNA targets.
Considering the above results pointing to RBM10 as
a modulator of the RLR signaling cascade, we evaluated
whether it could exert any effect on RIG-I ubiquitination,
one of the steps required for the activation of this cyto-
plasmic receptor upon viral RNA sensing. For this pur-
pose, cells were co-transfected with an expression vector
for 6xHis-Ubiquitin, one for Flag-tagged RIG-I and in-
creasing amounts of the T7-RBM10 coding plasmid. Pu-
rification of newly ubiquitinated proteins was achieved by
nickel affinity chromatography followed by detection of
ubiquitin-conjugated RIG-I by western blot. The results
from these experiments showed an increase in ubiquitinated
RIG-I triggered by RBM10 (Figure 6D) in a concentration-
dependent manner (Supplementary Figure S5B), without
any effect on Flag-RIG-I protein levels. These observations
are consistent with an RBM10-stimulated RIG-I activation.
Further studies will be required to conclude whether this ef-
fect is dependent on RBM10 activity as a splicing regulator
or could represent a novel, splicing-independent and cyto-
plasmic role for this protein.
DISCUSSION
Here, we report that SAT1 exon 4 alternative splicing is
affected by DENV infection of cultured human cells. It
is of note that the protein levels of the splicing factor al-
ready characterized to regulate this splicing event, RBM10,
are also affected. We propose that the DENV protein NS5
is responsible for RBM10 proteasomal degradation since
these two proteins interact and, more importantly, NS5
over-expression per se decreases RBM10 protein levels, in
a proteasome-dependent manner. Moreover, RBM10 over-
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Figure 6. RBM10 binds RIG-I and DENV genome and promotes RIG-I ubiquitination. (A) RBM10 and dsRNA (a marker of viral RNA) localization was
visualized by indirect immunofluorescence and nuclei-cytoplasmic ratio was quantified. (B) A549 cells were either treated with IFN  or DENV infected and
subjected to co-immunoprecipitation assays with anti-RBM10. RNase A (0.1 mg/ml) was added to lysates when indicated. Input and immunoprecipitated
fractions were analyzed by western blot with the corresponding antibodies. (C) RNA-immunoprecipitation (RIP) assays with anti-RBM10 of lysates from
A549 infected cells at 48 hpi. RT-qPCRs were performed with primers for SAT1 pre-mRNA and viral RNA and represented as RIP/input RNA. Average
values from triplicates are shown with standard deviation and p-values, determined using a paired two-tailed t-test. Significant P-values are indicated by
the asterisks above the graphs (***P < 0.001; **P < 0.01; *P < 0.05). (D) HEK 293T were transfected with the indicated expression vectors and after 48
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patterns to mock conditions but also severely diminishes vi-
ral replication. In contrast, RBM10 knock-down enhances
SAT1 splicing change and viral replication. Altogether,
these results led us to assign RBM10 an anti-viral role. In-
deed, induction of IFN and pro-inflammatory cytokines
downstream of RLR activation is attenuated upon RMB10
depletion. Co-immunoprecipitation experiments suggest an
RBM10 interaction with the RIG-I/DENV RNA ribonu-
cleoprotein complex, adding a new layer of complexity to
RBM10 pro-inflammatory anti-viral function besides its al-
ready described nuclear role in splicing regulation (23,30–
33,58). Furthermore, RBM10 enhances RIG-I ubiquitina-
tion, a crucial step required for activation of the innate re-
sponse.
We started this study by analyzing splicing changes upon
DENV infection from our previously reported RNA-seq ex-
periments (20). Host cell splicing changes upon viral infec-
tions as well as interference of the splicing machinery by
viral components have also been reported by other labora-
tories (46–48). In our case, we had found a significant in-
crease in intron retention and, to a lesser extent, changes
in alternative splicing patterns (20). Taking into account
the previously reported anti-viral function of SAT1 (10,12)
and the changes in the splicing pattern of its pre-mRNA
caused by other viruses (18), this transcript appeared as
an interesting candidate to begin elucidating the molecular
mechanism underlying DENV-triggered splicing regulation
within the complex and dynamic scenario of virus-host cell
interaction. In fact, in our RNA-seq dataset, in addition to
increased reads corresponding to alternative exon 4 upon
DENV infection, we also detected the retention of a big in-
tron encompassing exon 4 and flanking introns. This could
indicate an altered function of RBM10, which was reported
in several occasions to facilitate SAT1 exon 4 skipping. The
model proposed is that RBM10 binding in the vicinity of
splicing sites might repress the splicing of introns and de-
lay the splicing choice, thereby facilitating the skipping of
cassette exons (34). The fact that DENV infection affected
RBM10 protein levels as well as SAT1 alternative splicing
favoring exon 4 inclusion is consistent with this proposed
model.
We were able to detect changes in SAT1 splicing and
RBM10 protein levels both in A549 and HEK 293T cells.
This represented a validation of our previous RNA-seq re-
sults, performed in A549 cells. More importantly, splicing-
impairing mutations within RBM10 have been reported in
A549 cells. Indeed, RBM10 pro-apoptotic functions have
been attributed, at least in part, to its ability to regulate
NUMB splicing, which is diminished in these cells (21,32).
In this respect, it is important to mention that we used wild
type RBM10 for over-expression assays in our study, which
may account for induction of inflammatory genes even un-
der mock conditions (Figure 4B), particularly considering
the widely reported RBM10 lower expression in A549 cells
due to its self-splicing deregulation (35). In any case, this
highlights RBM10 relevance in inflammation and protec-
tion from infection. All things considered, we propose that
there is a conserved RBM10-mediated splicing regulation
upon DENV infection of the two cell lines tested, which is
supported by changes in SAT1 splicing and RBM10 protein
levels as well as a significant overlap of other splicing events
regulated both in DENV-infected A549 and HEK 293T
RBM10-KD cells. Moreover, A549 cells represent a suit-
able cell culture model for analyzing RLR signaling path-
way and inflammation upon DENV infection (49), which
might be attributed in part to their RBM10 lower levels
leading to delayed apoptosis as well as higher DENV infec-
tivity and higher impact on RBM10-dependent functions
upon its depletion.
RBM10 down-regulation upon DENV infection can be
explained by NS5-targeted proteasomal degradation. We
were able to detect a decrease in RBM10 protein levels not
only in infected cells but also in the context of NS5 over-
expression. However, IFN treatment or Poly I:C adminis-
tration does not seem to exert this effect. Mapping the ex-
act region within NS5 responsible for triggering RBM10
degradation, as well as understanding whether the phys-
ical interaction of these two proteins is required for this
regulatory mechanism warrants further investigation. Sev-
eral studies already reported the ability of NS5, or other
viral protein, to target host proteins for degradation (50–
54). Consistently, NS5 over-expression also affected SAT1
splicing patterns, which could be due to diminished RBM10
and/or to spliceosome misassembly, what was proved to
be triggered by NS5 (20). RBM10 has been shown to be
involved in spliceosome assembly (24,29) and we propose
that it could be within the context of the spliceosome that
NS5 and RBM10 interact. The interaction of these two pro-
teins is mainly supported by co-immunoprecipitation as-
says and is consistent with their subcellular co-fractionation
and nuclear co-localization. However, our previous mass
spectrometry analysis failed to detect RBM10 as an NS5
partner, even though it was significantly enriched in ZIKV
NS5 interactome (36). This discrepancy might be due to
DENV NS5-targeted RBM10 proteasomal degradation.
In any case, involvement of NS5 and RBM10 in spliceo-
some assembly is strongly supported by previous evidence
(20,24,26,29). The novelty for RBM10, revealed by the cur-
rent study, is that the cellular levels of this protein are re-
duced by DENV infection or NS5 expression, whereas the
levels of several analyzed spliceosomal proteins that were
identified as NS5-binders are not affected under similar
conditions (20).
RBM10 involvement in splicing is further supported by
its modular domain organization, which displays two RNA
binding motifs and three nuclear localization signals (23).
It is presumably due to these that its subcellular partition-
ing is mainly nuclear, even though we detected a decrease
in nuclei-to-cytoplasmic localization ratio upon infection.
Whether RBM10 interaction with DENV RNA and RIG-I
receptor, which is known to detect viral cytosolic RNA and
to trigger anti-viral signaling towards nuclear transcription,
can account for this partial re-localization of RBM10 war-
rants further investigation. Our results suggest that RBM10
and RIG-I interact also in the absence of DENV RNA
(i.e. IFN alone or DENV with RNase A treatment, Figure
6B). However, DENV RNA could still function as a scaf-
fold and facilitate the encounter. Several splicing and RNA
processing factors have been found to interact with DENV
genome by mass spec analysis, particularly with the 3′UTR
region (55–57). Since several sequences have been spotted
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Figure 7. Impact of DENV on RBM10 and its consequences on splicing, inflammation and viral replication. Nuclear RBM10 regulates alternative splicing
favoring anti-viral mRNA isoforms, among which SAT1 isoforms were investigated in this report. Upon DENV infection, NS5 intrudes into the spliceo-
some, as previously reported by our laboratories, and also targets RBM10 for proteasomal degradation, favoring pro-viral splicing isoforms. On the other
hand, RMB10 also interacts with viral genome and RIG-I and promotes the ubiquitination of the latter, which is known to be required for its activation and
the induction of the innate immune response. Overall, RBM10 is required for the induction of interferon and pro-inflammatory cytokines. Whether this is a
result of RBM10 involvement in splicing regulation, or in RIG-I/DENV genome ribonucleoprotein complex, or both, remains an intriguing question. The
fact is that higher protein levels of RBM10 correlate with an anti-viral, pro-inflammatory scenario while lower levels with a pro-viral, anti-inflammatory
one.
tion is required to identify them within the DENV genome
as well as to decipher the functional consequences of this
RBM10–viral RNA interaction. In any case, we report that
RBM10 associates with RIG-I, which could provide a novel
cytoplasmic role for RBM10 in regulating inflammation,
although we do not rule out that RBM10 also plays pro-
inflammatory tasks in the nucleus, where it is mainly local-
ized. In fact, it has been reported that RBM10 promotes in-
flammation by modulating alternative splicing of Dnmt3b,
which codes for a DNA methyl transferase known to regu-
late the activity of NF-B-responsive promoters and conse-
quently inflammation development (58).
It is known that eukaryotic cells rely on the innate im-
mune response to limit viral replication and a great amount
of proteins has been identified to participate and/or coop-
erate with this cellular program (59–62). Our results point
to RBM10 as fitting into this group and exerting an anti-
viral function at least in part through its ability to regu-
late splicing patterns towards the production of anti-viral
and pro-inflammatory mRNA isoforms, in particular with
respect to SAT1 pre-mRNA. However, we cannot rule out
other non-splicing related functions of RBM10, especially
after observing its co-purification with DENV RNA as well
as with the viral sensor RIG-I. Whether these interactions,
which are supposed to take place in the cytoplasm, have
anything to do with the regulation of RBM10 activity as
a pre-mRNA processing factor (21,32,34,37,63) and/or are
related to a novel cytoplasmic role for RBM10 remains to be
further studied. Also, we have detected that RBM10 stim-
ulates at least one step along the RIG-I activation process
that is its ubiquitination. Again, whether this effect depends
on RBM10–RIG-I interaction or is mediated by RBM10-
dependent splicing regulation is still an intriguing question
(Figure 7, left side). On the other hand, viral pathogens have
evolved sophisticated mechanisms to counteract the cellu-
lar response (62). Considering our previous and current re-
sults, we propose that several events could take place in the
context of DENV infection and contribute to alter host cell
splicing patterns and to attenuate the innate response lead-
ing to a more permissive environment for viral replication.
So far we can mention the already reported intrusion of
NS5 into the spliceosome (20) as well as NS5–RBM10 inter-
action, NS5-triggered RBM10 degradation, and potentially
RBM10 partial re-localization, as putative levels of viral ac-
tion (Figure 7, right side).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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